Lipid-based Drug Delivery of Cannabinoids
While per-oral delivery is the patient-preferred route of administration, the per-oral dosing of cannabinoid actives is not trivial. Due to low solubility and extensive first pass metabolism, the per-oral dosing of cannabinoid actives often results in relatively low bioavailability. Lipid-based drug delivery, including self-emulsifying drug delivery, readily provides for improved per-oral solubility and bioavailability of cannabinoid actives, increasing the therapeutic effectiveness of these products.
Key Learning Objectives
- How lipids improve the per-oral solubility and bioavailability of cannabinoids
- How to formulate self-emulsifying cannabinoid delivery systems
- How to analyze emulsion characteristics
This LIVE event has already taken place
Fill out form below to access the recorded version of this event and receive a copy of the presentation.
Webinar Speakers
John Tillotson R.Ph., Ph.D.
Technical Business Director, Canada, Latin American and India
ABITEC Corporation
Alice Hirschel, Ph.D.
Technical Business Director, Pharmaceutical and Nutritional Health
ABITEC Corporation
Dr. Alice Hirschel has 10 years of research in disease nutrient-interactions and 10 years product and commercial development experience in the food and nutrition industry. She graduated with a BS in Nutritional Sciences from the University of Georgia and a PhD in Nutritional Sciences from the University of Texas at Austin. Dr. Hirschel began formulating supplements as a Product Development Scientist at GNC. She transitioned to Commercial Development with Innophos Nutrition and now, Dr. Hirschel works in technical, commercial and business development, learning to execute sales and marketing strategies with ABITEC Corporation.